La cadena de opciones muestra datos clave de las opciones de acciones de Eli Lilly a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Eli Lilly..

Eli Lilly (NYSE:LLY) Bolsa, Cadena de Opciones

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

manufacturing PMI

Long Ideas

Trading Ideas

AAPL

NVDA

Apple, Nvidia, TSMC y otras grandes empresas están trayendo su producción de vuelta a EE. UU. en una nueva ola de relocalización.

Gigantes tecnológicos y fabricantes de EE. UU. apuestan por relocalizar su producción: ¿Vuelve el &#34;Made in USA&#34;?

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

US CHINA FLAG Photo by asiandelight on Shutterstock

Tech

Media

Michael Kratsios toma las riendas de la inteligencia artificial en EE. UU. con un plan estratégico para contener a China.

Michael Kratsios lidera estrategia de IA en EE. UU. para frenar el avance de China

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

<a href="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss" title="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss">https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss</a>

Biotech

General

'GLP-1 Drugs May Be Linked To Elevated Risk Of Serious Eye Disease, Study Finds' - STAT News

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Upgrades

Health Care

Analyst Ratings

Movers

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKBA

MRNA

NTRA

SRDX

TEVA

9 Health Care Stocks Whale Activity In Today's Session

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

<a href="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html" title="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html">https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html</a>

"Exclusive: Ozempic Linked To 'Silent Cancer' That Is Rising In Young People As Doctors Issue Shock Warning" - DailyMail+

Summer is almost here, and investors are hunting for fresh opportunities after the S&amp;P 500 logged its strongest <a href="https://www.benzinga.com/markets/equities/25/05/45704748/magnificent-seven-drive-wall-streets-rally-nvidia-notches-best-month-in-a-year-this-week-in-markets">month since November 2023. </a>
According to Seasonax data, looking at 97 years of history, the S&amp;P 500 averages a 0.7% gain in June. In recent times, performance has been even better: over the past six years, the index has ended June higher five times, with an average return of 2.1%.
Thus, June has historically brought more gains than pain, and certain S&amp;P 500 stocks have a consistent track record of outperforming in this early-summer stretch.
<h3 class="wp-block-heading">Top 10 June Stocks Based On 10-Year Seasonal Performance</h3>
An analysis of S&amp;P 500 components between June 2 and July 2 over the past 10 years reveals clear outperformers. Here are the top 10 stocks ranked by average return during this 30-day window. 
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is by far the top June performer, with an average return of 14.5%, beating the S&amp;P 500 by a wide margin. It closed positively in 8 out of the last 10 Junes, with the best return — a 37.1% rally — coming in 2023.
Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has been the most consistent performer on this list, with 9 wins in 10 years. Its June gains have averaged 6.2% over the past decade, with a peak return of 17.5% in 2021 and a minimal drawdown of -2.2% in 2019.
Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) also ranks high with a 5.6% average return. Notably, in the last two Junes, the tech company rose by 17% and 24.9% respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg Return</th>
<th>Win Rate</th>
<th>Max Gain</th>
<th>Worst Drop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesla </td>
<td>+14.5%</td>
<td>8/10</td>
<td>+37.1%</td>
<td>-9.8%</td>
</tr>
<tr>
<td>Eli Lilly </td>
<td>+6.2%</td>
<td>9/10</td>
<td>+17.5%</td>
<td>-2.2%</td>
</tr>
<tr>
<td>Adobe </td>
<td>+5.7%</td>
<td>6/10</td>
<td>+29.3%</td>
<td>-14.7%</td>
</tr>
<tr>
<td>Oracle Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NASDAQ">ORCL</a>)</td>
<td>+4.9%</td>
<td>7/10</td>
<td>+20.1%</td>
<td>-7.6%</td>
</tr>
<tr>
<td>Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>+4.9%</td>
<td>6/10</td>
<td>+31.2%</td>
<td>-19.4%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+4.3%</td>
<td>7/10</td>
<td>+16.9%</td>
<td>-9.6%</td>
</tr>
<tr>
<td>Digital Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</td>
<td>+4.0%</td>
<td>7/10</td>
<td>+15.5%</td>
<td>-6.2%</td>
</tr>
<tr>
<td>Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>)</td>
<td>+4.0%</td>
<td>6/10</td>
<td>+11.5%</td>
<td>-5.5%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>+3.7%</td>
<td>5/10</td>
<td>+17.0%</td>
<td>-7.7%</td>
</tr>
<tr>
<td>Fair Isaac Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</td>
<td>+3.7%</td>
<td>8/10</td>
<td>+18.2%</td>
<td>-1.96%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value </a></li>
</ul>
Photo: Shutterstock

Large Cap

ADBE

AMZN

FICO

GNRC

ORCL

TSLA

Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June

Penny stock Veru Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patients over 60 years receiving Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) for <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">chronic weight management</a>.
The enobosarm and semaglutide GLP-1 RA combination had a favorable safety profile in the trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43237532/veru-shares-tumble-despite-enobosarms-lean-muscle-preservation-breakthrough" rel="noreferrer noopener">Veru Shares Tumble Despite Enobosarm&#8217;s Lean Muscle Preservation Breakthrough</a>
There were no increases in gastrointestinal side effects. There is also no evidence of drug-induced liver injury, or increases in obstructive sleep apnea at any dose of enobosarm compared to the placebo. 
There were no AEs of increases in prostate-specific antigen in men. There were no AEs related to masculinization in women. There were no reports of suicidal ideation observed.
No treatment-related serious adverse events (SAEs) were observed in the QUALITY study.
At the proposed Phase 3 program dose of enobosarm 3mg, one subject experienced an adverse event of a transient, mild increase in alanine aminotransferase (ALT), which returned to baseline while remaining on enobosarm.
There were no accompanying increases in aspartate aminotransferase (AST), alkaline phosphatase, or total bilirubin.
The data shows that adding enobosarm 3mg to <a href="https://www.benzinga.com/pressreleases/25/05/g45639117/veru-reports-positive-safety-results-from-phase-2b-quality-study-enobosarm-added-to-semaglutide-le" target="_blank" rel="noreferrer noopener">semaglutide</a> created a more selective weight loss profile, with 99.1% of weight loss coming from fat rather than muscle compared to 68% in the semaglutide plus placebo arm.
The&nbsp;Stair Climb Test&nbsp;showed that 42.6% of semaglutide-only patients experienced significant functional decline equivalent to 7.5 years of aging, while only 16% of the enobosarm 3mg combination group showed a similar decline, translating to a 62.4% relative reduction in functional deterioration.
The enobosarm 6mg + semaglutide dose did not provide any additional benefit over the 3mg dose in preserving lean mass.
The company plans to propose a Phase 3 program similar to the Phase 2b QUALITY trial in older patients. The GLP-1 RA may be either Wegovy and/or Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide).
Price Action: VERU stock is up 22.5% at 62 cents at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45643704/ford-recalls-11-million-vehicles-for-camera-software-issue-report" target="_blank" rel="noreferrer noopener">Ford Recalls 1.1 Million Vehicles For Camera Software Issue: Report</a></li>
</ul>
Image: Shutterstock

VERU

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

In the current market session, Eli Lilly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) price is at $725.96, after a 1.72% increase. However, over the past month, the stock decreased by 17.99%, and in the past year, by 10.54%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1748376027_0.png" alt="Past Year Chart" />

<h3>Eli Lilly P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 26.38 in the Pharmaceuticals industry, Eli Lilly Inc. has a higher P/E ratio of 58.07. Shareholders might be inclined to think that Eli Lilly Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748376027_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Eli Lilly

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is on track to close one of its worst months ever after slashing its full-year profit outlook despite beating <a href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say">first-quarter earnings estimates. </a>
But a glimmer of hope lies ahead, as June historically stands out as the drugmaker's best month of the year.
Shares of Eli Lilly are down 19% in May, pacing for their worst monthly performance since February 2009. However, the underperformance compared to the broader market has been even more severe.
The stock has lagged the S&amp;P 500 Index by 23.8% this month — the steepest relative decline since August 2000 and the second-largest since the company went public in 1970.
<h3 class="wp-block-heading">Chart: Eli Lilly Suffered One Of Its Worst Months Ever</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png" alt="" class="wp-image-928926" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Sparked The Selloff?</h3>
The sharp move followed the company's May 1 quarterly earnings. While Lilly posted better-than-expected first-quarter results, the stock plunged 12% that day — the worst single-session drop since August 2000.
The decline was triggered by a sharp cut in the company's full-year profit forecast. Eli Lilly cited $1.57 billion in acquired in-process research and development (IPR&amp;D) charges, primarily tied to its acquisition of a cancer therapy from Scorpion Therapeutics. While sales guidance remained unchanged, full-year profit expectations were revised downward to reflect those R&amp;D costs.
For 2025, Eli Lilly projects revenue between $58 billion and $61 billion, implying a 32% year-over-year increase.
&#8220;Expect volatility, take advantage of moment of weakness, as long as there is not a new, fundamental crack in the story,&#8221; said Bank of America analyst Tim Anderson. The firm reaffirmed its 12-month price target of $1,000, suggesting a 38% upside from current levels.
<h3 class="wp-block-heading">Could June Offer Relief?</h3>
While May has battered Lilly shareholders, June has historically brought better fortune. Over the past 30 years, shares have gained an average of 2.94% during the month, according to TradingView data.
June is statistically Eli Lilly's best month, with a 67% chance of closing higher. 
Even more notable: the past five Junes have all ended in the green. The best June performance came in 2000 when the stock surged 28.1%. Only two Junes in recent history delivered double-digit losses — in 2001 and 2019, both dropping 10.6%.
There's precedent for a bounce. In 1997 and 2003, Eli Lilly dropped more than 10% in May. In both cases, shares recovered in June with gains of 3.9% and 14.1%, respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Year</th>
<th>$LLY June Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>3.00%</td>
</tr>
<tr>
<td>1996</td>
<td>0.94%</td>
</tr>
<tr>
<td>1997</td>
<td>12.65%</td>
</tr>
<tr>
<td>1998</td>
<td>3.85%</td>
</tr>
<tr>
<td>1999</td>
<td>-4.91%</td>
</tr>
<tr>
<td>2000</td>
<td>28.14%</td>
</tr>
<tr>
<td>2001</td>
<td>-10.58%</td>
</tr>
<tr>
<td>2002</td>
<td>-5.98%</td>
</tr>
<tr>
<td>2003</td>
<td>14.10%</td>
</tr>
<tr>
<td>2004</td>
<td>-6.78%</td>
</tr>
<tr>
<td>2005</td>
<td>-4.43%</td>
</tr>
<tr>
<td>2006</td>
<td>7.02%</td>
</tr>
<tr>
<td>2007</td>
<td>-2.95%</td>
</tr>
<tr>
<td>2008</td>
<td>4.90%</td>
</tr>
<tr>
<td>2009</td>
<td>0.18%</td>
</tr>
<tr>
<td>2010</td>
<td>7.98%</td>
</tr>
<tr>
<td>2011</td>
<td>-0.66%</td>
</tr>
<tr>
<td>2012</td>
<td>0.80%</td>
</tr>
<tr>
<td>2013</td>
<td>-6.19%</td>
</tr>
<tr>
<td>2014</td>
<td>1.92%</td>
</tr>
<tr>
<td>2015</td>
<td>8.09%</td>
</tr>
<tr>
<td>2016</td>
<td>4.86%</td>
</tr>
<tr>
<td>2017</td>
<td>2.94%</td>
</tr>
<tr>
<td>2018</td>
<td>-0.14%</td>
</tr>
<tr>
<td>2019</td>
<td>-10.60%</td>
</tr>
<tr>
<td>2020</td>
<td>5.40%</td>
</tr>
<tr>
<td>2021</td>
<td>12.41%</td>
</tr>
<tr>
<td>2022</td>
<td>12.92%</td>
</tr>
<tr>
<td>2023</td>
<td>2.56%</td>
</tr>
<tr>
<td>2024</td>
<td>6.67%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Average</td>
<td>2.94%</td>
</tr>
</tfoot>
</table>
</figure>
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">Goldman Sachs Taps This Defense Stock As Prime Beneficiary Of Trump&#8217;s $175B Golden Dome</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45618809/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics" rel="noreferrer noopener">studied for pain</a>.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say" rel="noreferrer noopener">Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say</a>
&#8220;The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive,&#8221; said Mark Mintun, Lilly group vice president of Neuroscience Research and Development. &#8220;Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies.&#8221;
Under the terms of the agreement, Lilly will acquire SiteOne, and SiteOne shareholders could receive up to $1 billion in cash, including an upfront payment and subsequent payments upon achieving certain regulatory and commercial milestones.
Earlier in May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with&nbsp;Rznomics Inc.,&nbsp;a&nbsp;South Korea-based biopharmaceutical company specializing&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" rel="noreferrer noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
If Lilly exercises all available options under the agreement, the total deal value could reach more than&nbsp;$1.3 billion, and separate royalties on product sales. The upfront payment was not disclosed.&nbsp;
Price Action: LLY stock is up 1.7% at $726.14 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45626048/why-marvells-ai-revenue-could-top-4-billion-by-2025-analyst-explains" target="_blank" rel="noreferrer noopener">Why Marvell&#8217;s AI Revenue Could Top $4 Billion By 2025, Analyst Explains</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/30/25</td>
<td>$65.00</td>
<td>$37.4K</td>
<td>872</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$302.0K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$850.00</td>
<td>$33.5K</td>
<td>31.4K</td>
<td>798</td>
</tr>
<tr>
<td>VERA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$30.00</td>
<td>$41.1K</td>
<td>446</td>
<td>342</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$400.00</td>
<td>$33.4K</td>
<td>1.9K</td>
<td>282</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$65.00</td>
<td>$104.7K</td>
<td>114</td>
<td>162</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$111.8K</td>
<td>2.1K</td>
<td>105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$215.00</td>
<td>$54.2K</td>
<td>385</td>
<td>87</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$28.8K</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>ONC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$220.00</td>
<td>$32.2K</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a put option trade with neutral sentiment. It expires in 3 day(s) on May 30, 2025. Parties traded 170 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $37.4K, with a price of $220.0 per contract. There were 872 open contracts at this strike prior to today, and today 1645 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option trade that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 1000 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $302.0K, with a price of $302.0 per contract. There were 5187 open contracts at this strike prior to today, and today 1108 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $850.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.5K, with a price of $335.0 per contract. There were 31403 open contracts at this strike prior to today, and today 798 contract(s) were bought and sold. 
• For VERA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), we notice a put option sweep that happens to be bullish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 34 contract(s) at a $30.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $1210.0 per contract. There were 446 open contracts at this strike prior to today, and today 342 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 598 day(s) on January 15, 2027. This event was a transfer of 10 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $3342.0 per contract. There were 1906 open contracts at this strike prior to today, and today 282 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 570 day(s) on December 18, 2026. This event was a transfer of 161 contract(s) at a $65.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $104.7K, with a price of $655.0 per contract. There were 114 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on August 15, 2025. Parties traded 87 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $111.8K, with a price of $1286.0 per contract. There were 2152 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bullish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 67 contract(s) at a $215.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $810.0 per contract. There were 385 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 40 contract(s) at a $80.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $720.0 per contract. There were 50 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we notice a call option trade that happens to be neutral, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 15 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VERA

VRNA

10 Health Care Stocks Whale Activity In Today's Session

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 63 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $987,598, and 50 were calls, valued at $9,378,343.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $220.0 to $1000.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly's substantial trades, within a strike price spectrum from $220.0 to $1000.0 over the preceding 30 days.
<h3>Eli Lilly 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748361636_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.5</td>
<td>$7.95</td>
<td>$7.95</td>
<td>$850.00</td>
<td>$4.2M</td>
<td>770</td>
<td>6.6K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$7.9</td>
<td>$7.5</td>
<td>$7.9</td>
<td>$850.00</td>
<td>$1.2M</td>
<td>770</td>
<td>1.4K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.55</td>
<td>$2.26</td>
<td>$2.27</td>
<td>$950.00</td>
<td>$1.1M</td>
<td>564</td>
<td>6.6K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.58</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$950.00</td>
<td>$350.1K</td>
<td>564</td>
<td>1.4K</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$65.45</td>
<td>$58.65</td>
<td>$61.7</td>
<td>$600.00</td>
<td>$308.5K</td>
<td>1.0K</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a trading volume of 1,509,635, the price of LLY is up by 1.2%, reaching $722.3.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Eli Lilly</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $875.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from HSBC downgraded its action to Reduce with a price target of $700. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1050. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In LLY Options

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 5.2% on an annualized basis producing an average annual return of 13.45%. Currently, Eli Lilly has a market capitalization of $645.87 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $12,357.62 today based on a price of $719.09 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748355313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management
INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
Under the terms of the agreement, Lilly will acquire SiteOne and SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.

Eli Lilly To Acquire SiteOne Therapeutics in $1B Deal, Expanding Non-Opioid Medicines For Pain Management

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). &#8220;I just think this is a decent level to start a position if you don't have any<a href="https://www.benzinga.com/quote/LLY">,</a>&#8220;<a href="https://www.benzinga.com/quote/LLY"> he noted</a>.
As per recent news, Lilly&#8217;s Kisunla (donanemab) received marketing authorization in Australia on May 21 for the treatment of early symptomatic Alzheimer&#8217;s disease.
&#8220;That one's done,&#8221; Cramer said when asked about Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>). &#8220;I say take your money out that you put in and then you can let the rest ride.&#8221;
Nvidia, last week, selected the company to collaborate on 800V HVDC architecture.
Cramer recommended taking profit from Mr. Cooper Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>). &#8220;That thing's done,&#8221; he added.
Supporting his view, Mr. Cooper posted weaker-than-expected quarterly sales on April 23.
Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is &#8220;just one darn crazy&#8221; stock, adding that the stock is not making any money.
On the earnings front, Red Cat reported first-quarter revenue of $1.63 million on May 14, missing analyst estimates of $3.85 million. The company reported a first-quarter loss of 27 cents per share, missing analyst estimates for a loss of eight cents per share, according to Benzinga Pro.
Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) is a &#8220;very fine&#8221; company, Cramer said.
Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales.
&#8220;I've got to tell you, I am not in the oil service business,&#8221; Cramer said when asked about Liberty Energy Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBYE#OTC">LBYE</a>). He said he didn&#8217;t &#8220;care for the stock&#8221; of Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) but liked Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The Mad Money host said he likes Rio Tinto Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>).
As per recent news, Rio Tinto on Thursday disclosed that its CEO, Jakob Stausholm, will step down later this year. Jakob joined the company in 2018 as executive director and CFO and took on the role of CEO in January 2021.
When asked about DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>), Cramer recommended buying Bitcoin (CRYPTO: BTC).
On May 16, DeFi Development announced a partnership with BONK to operate and manage a jointly backed validator node.
Price Action:
<ul class="wp-block-list">
<li>Eli Lilly shares fell 0.2% to settle at $713.71 on Friday.</li>
<li>Navitas shares declined 12.7% to close at $4.41 during the session.</li>
<li>Rocket shares gained 0.9% to settle at $12.68.</li>
<li>Rio Tinto shares gained 0.8% to close at $61.58.</li>
<li>DeFi Development shares dipped 18.9% to settle at $34.45 on Friday.</li>
<li>Red Cat shares gained 1.3% to settle at $6.82 on Friday.</li>
<li>Liberty Energy shares closed at 0.0001 during the session.</li>
<li>Mr. Cooper shares gained 1.6% to close at $129.50.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo: Shutterstock

$BTC

COOP

DFDV

LBYE

NVTS

RCAT

Jim Cramer Says Rocket Is A 'Very Fine' Company, Recommends Buying This Health Care Stock

Everybody "knows" that value investing doesn't work anymore. It's in all the headlines.
Investing today is about technology, everyone says. It's about artificial intelligence. It's about quantum computing, about the rebirth of nuclear energy.
Some of this is true, some isn't, but what's really not true is that value investing doesn't work. In fact, it still works better than just about any other investing approach.
The reason people say otherwise is because they've got value all wrong. "Value," they think, is just another word for "cheap." But most cheap stocks are cheap because they're bad investments.
Here's how to invest in value the right way using just two metrics – and beat the markets handily.
<h2 class="wp-block-heading">What People Get Wrong About Value</h2>
There are a couple of problems with the way people define value investing. First, we need to address the fact that the sound of it is boring.  Value investing sounds like a professor with tweed elbow patches smoking a pipe in an old dusty office in some brick and ivy university somewhere up in Vermont or Maine during a snowstorm. It just sounds boring.
Perhaps if we could call it vulture investing, market pillaging, or some other equally interesting name, it would attract more attention.
But then again, since we seem to have a corner on it, do we really want to attract all that much attention?
Second, let's talk about the way people track value. For instance, the Russell Value Index is supposed to represent value. When you compare it, growth has outperformed value for several hundred consecutive years, according to the literature.
That may be a slight exaggeration, but you get the point.
When you examine the Russell 1000 Value index, it's allegedly the bottom half of the Russell 2000 weighted by value components.
The top holdings include Berkshire Hathaway, Cisco Systems, McDonald&#8217;s, Walt Disney, Raytheon, and Caterpillar. These are all great companies.
What they are not is value companies.
<h2 class="wp-block-heading">The Truth About Value</h2>
When we really look at the hard data, the truth is that absolute value never stopped working. When you look at companies that are trading at discounts to asset value, low multiples of the cash produced by the business, and low multiples of liquidation value, which is still one of my favorites, the truth is that they have continued to work and work very well.
The key thing that most people leave out is they will run a list of companies trading below book value and will say, &#8220;Look, these underperformed the market.&#8221; That is, in fact, true.
More than half of those companies are unprofitable and overleveraged, and their products are going completely out of style. You know, they are CD-ROM manufacturers or buggy whip makers in the business of making something we are never going to use again.
Many of the companies that trade below book value, in all honesty, do so for a reason. They are headed for the garbage pile.
<h2 class="wp-block-heading">Making Value Work: Financial Strength</h2>
How do we get rid of those? You have to adjust for a couple of factors:
<ul class="wp-block-list">
<li>You want strength in the financial statements.</li>
<li>You want the ability to survive, and you prefer that they are profitable.</li>
</ul>
Two papers, with several follow-ups, have come out in the last twenty-five years that show us how to do this.
One of these is Joseph Piotrowski&#8217;s publication &#8220;Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers.&#8221; The F-score is based on that paper.
Value plus the F-score crush the market. When we add value plus the F-score plus credit scores, I prefer the Altman Z score—then you annihilate the market.
The key variable here is profitability and financial strength.
<h2 class="wp-block-heading">The Missing Factor: Profitability</h2>
The other paper, which very few people seem to have read, is important.
In 2013, an economist, Robert Novy-Marks, published a paper that should have but didn&#8217;t redefine the entire playing field for investing. It is called &#8220;The Other Side of Value: The Gross Profitability Premium.&#8221;
Basically, they found that highly profitable companies outperform, no matter how cheap or expensive they may look. It is a single idea that gross profitability is the missing dimension, the missing factor.
It has found its way into some of the academic models. Novy-Marksed followed up on it with &#8220;Profitability Retrospective: What Have We Learned?&#8221;
This is key because many people today will tell you that quality matters. We have got to buy these quality companies. Everyone has a 16, 17, or 18-factor model that supposedly helps us identify truly high-quality companies.
Novy-Marks has found in both the original 2013 study and the retrospective today that you only need one factor to identify quality. That factor is profitability, which is defined in the original paper as gross profits as a percentage of assets.
The higher that is, the better the company is.
<h2 class="wp-block-heading">Quality Simplified</h2>
It explains all of the excess returns from so-called quality investing. When you ask what exactly we are looking for here, it turns out it all boils down to one simple measure.
You can use an 18-factor model, or you can use just gross profitability as a percent of assets. When you look at the largest cap companies that are in the upper end of the range: Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), MasterCard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), UnitedHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), T-Mobile (NASDAQ: TMUS) &#8211; all of the same companies that would show up if we use that super sophisticated, 18-factor quality model for which you will pay a massive premium to have access to the data – it turns out you can get the same list using just gross profitability.
Gross profitability also explains all of the defensive strategies.
All of the defensive low beta stocks are just highly profitable companies that also are growing their asset base slowly. They are doing very conservative investing. They are not de-worsifying the business. They are not trying to grow at a high rate.
They are just ridiculously profitable companies that are willing to sit in place and do what they are good at and continually pile up profits and cash.
<h2 class="wp-block-heading">Unifying Factor</h2>
Profitability explains quality. It explains the low beta and low volatility phenomena.
Many investors have looked for new ways to define value. Cash flow to price, earnings forecast, intangible adjusted tangible book value, adjust for a lot of different factors in R&amp;D. These are going to "fix" value's alleged shortcomings in a day and age of high technology.
The truth is that all these newer value strategies sneak in profitability as a factor in addition to value. Profitability by itself delivers market-beating returns.
Profitability plus value, whether that is price to book or a different model that works, like enterprise value to earnings before interest and taxes, beats the market even more.
<h2 class="wp-block-heading">Why Value Appears to Have Underperformed</h2>
When we look at the underperformance of "value" since 2007, the truth is that it's because we junked up the value universe. We put a lot of garbage in there. There are many stocks trading below book value that are biotech startup companies. They are below the cash balance on the balance sheet, but they are burning cash at a rapid rate and will soon be out of money. The book value will, in fact, disappear.
There are all these companies that look cheap but are wildly unprofitable. They are burning through money.
Then you have a lot of garbage that came in through the two SPAC movements in 2007 and then again in 2020 when companies that were still basically at the garage stage of existence suddenly went public.
We really junked up the value universe with a lot of garbage.
<h2 class="wp-block-heading">The Foundation of Investment Success</h2>
Profitability is not just another factor but another tool.
It is a foundational tool that unifies multiple styles. It is part of quality, defensive value, and even some growth stocks.
Profitability explains a lot of the strategies that people use without relying on complicated, expensive 18-factor models.
If we take low-volatility companies and buy the most profitable, we are going to outperform the market.
If we just buy the most profitable companies, we are going to outperform the market.
If we buy the most profitable companies that are trading at low multiples of the cash produced by the business, we are going to absolutely crush the markets.
This is not a day trading system or a short-term trading system. It is the single best way to build long-term portfolios that beat the market and produce lasting wealth.
<h2 class="wp-block-heading">The Unified Theory of Investing</h2>
Profitability explains almost everything that happens in the market. If you have a great business, it is wildly profitable.
If you are a quality company with high returns on equity, low leverage, and earning stability, you are a very profitable company.
If you are a defensive company with low volatility and lower beta, all of the outperformance of these strategies is because they are profitable companies that are not reinvesting in the business to rapidly grow the asset base.
You have low-investment, profitable companies. There is your entire defensive strategy.
The underperformance of value investing over the last fifteen years or so is entirely because of the addition of so many unprofitable companies. If we use F-scores and profitability to screen out just the profitable undervalued companies, performance goes through the roof.
<h2 class="wp-block-heading">The Simple Path to Success</h2>
Most people won't do it because it doesn't make you rich by next Tuesday. It is not the absolute most exciting strategy on the planet. What it does is give you a very easy, quick way to uncover opportunities.
Two scores.
That is all you have to check. You can put together a universe of companies that can crush the market.
Basically, no folks, value investing is not dead.
If anything, if you understand that financial strength and profitability are the key to making value investing go from boring to the most exciting thing you can possibly do with your money, value investing is very much alive and still very successful.
<h2 class="wp-block-heading">Want to Trade the Next Reversal? Start Here</h2>
Matt Maley is watching one ultra-liquid ETF that surges when the market pulls back. He's used it time and time again—and this Wednesday at 6 PM ET, he'll be live to show you how to time it with precision. It's perfect for short-term traders looking to get ahead of the next move. Register <a href="https://events2.benzinga.com/matt-maley-webinar-wed-may28-2025-registration/?utm_campaign=webinar052825&amp;utm_adType=sponsorad&amp;utm_ad=RD052725">HERE</a> for this free masterclass now.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

GOOGL

TMUS

Value Investing Is Not Dead - It Just Got Smarter

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

5 Health Care Stocks Whale Activity In Today's Session

The authorization in Australia is for adult patients who are Apolipoprotein E-ε4&nbsp;heterozygotes or non-carriers
INDIANAPOLIS, May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε4)&nbsp;heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. Kisunla can help remove the excessive buildup of amyloid plaques and help slow the cognitive and functional decline in patients with early symptomatic Alzheimer's disease.

Global

Eli Lilly & Co Announces Kisunla (Donanemab) Receives Marketing Authorization In Australia For The Treatment Of Early Symptomatic Alzheimer's Disease

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 29 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 24% bearish. Among these notable options, 7 are puts, totaling $260,924, and 22 are calls, amounting to $965,029.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $640.0 to $1040.0 for Eli Lilly over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $640.0 to $1040.0 in the last 30 days. 
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747854167_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$121.45</td>
<td>$119.1</td>
<td>$120.35</td>
<td>$700.00</td>
<td>$120.3K</td>
<td align="right">400</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$66.0</td>
<td>$65.15</td>
<td>$66.0</td>
<td>$750.00</td>
<td>$66.0K</td>
<td align="right">305</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$63.0</td>
<td>$60.0</td>
<td>$60.0</td>
<td>$1000.00</td>
<td>$60.0K</td>
<td align="right">981</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$27.45</td>
<td>$26.8</td>
<td>$27.0</td>
<td>$870.00</td>
<td>$59.4K</td>
<td align="right">92</td>
<td align="right">25</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$58.2</td>
<td>$57.0</td>
<td>$57.49</td>
<td>$750.00</td>
<td>$57.4K</td>
<td align="right">279</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a volume of 2,435,598, the price of LLY is down -2.32% at $729.66. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $908.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $975. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Eli Lilly with a target price of $1050. 
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $700.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Eli Lilly Options Trading: A Deep Dive into Market Sentiment

President Donald Trump has touted multi-trillion-dollar investment commitments as proof that his economic strategy is delivering a historic revival of <a href="https://www.benzinga.com/topic/donald-trump">American manufacturing and infrastructure. </a>
Yet, behind the massive figures, new analysis from Goldman Sachs suggests the actual economic impact could be far more modest.
Foreign governments and corporations have pledged over $6 trillion in U.S. investments, including $2 trillion from companies and $4.2 trillion from foreign governments, according to Goldman Sachs economist Joseph Briggs.
Just a week ago, President Trump secured $2 trillion in investment commitments from Gulf nations, including Saudi Arabia, Qatar and the United Arab Emirates. Meanwhile, Japan pledged $1 trillion.
Among the companies making the largest pledges, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) announced $787 billion, followed by International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with $409 billion, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with $302 billion, and Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with $35 billion.
"We expect the impact on U.S. investment to be smaller than suggested by these promises for three reasons," Briggs said in a report, highlighting project uncertainty, limited alignment with national accounts definitions, and overlap with prior plans.
<h3 class="wp-block-heading">The Real Investment Boost May Be Just $30B–$135B</h3>
After analyzing the announcements and stripping out less tangible commitments—like purchases of goods, partnerships, and reannounced projects—Goldman estimates that only $135 billion in new annual investment is directly tied to GDP-relevant projects like physical capital expenditures and R&amp;D. 
Applying historical realization rates and analyst feedback, the bank sees the likely net impact closer to $30 billion per year, or just 0.1% of U.S. GDP.
That figure starkly contrasts with headline projections that initially suggested a 4% GDP boost over time.
<h3 class="wp-block-heading">Why The Gap?</h3>
Many large-cap companies, including Apple Inc. and Nvidia Corp., have promised massive investments—$500 billion each over multiple years—but their past spending doesn't align. 
Apple spent just $10 billion on U.S. capex and $31.4 billion on global R&amp;D in 2024. Nvidia's corresponding figures were even lower, suggesting that headline figures may include spending on acquisitions, partnerships or input costs that don't translate into actual U.S. capital formation.
Further, Goldman's equity analysts found that 69% of the corporate investments likely overlap with previously planned spending, with just 6% seen as mostly new.
Goldman Sachs noted that &#8220;these announcements have not driven major upgrades to equity analyst capex forecasts.&#8221;
<h3 class="wp-block-heading">Foreign Deals May Help, If They Materialize</h3>
&#8220;In contrast to company-level announcements, investment promises from the United Arab Emirates, Saudi Arabia, Qatar, and Japan could provide a material incremental increase if they materialize,&#8221; Briggs said.
Countries like Saudi Arabia, Qatar, Japan and the UAE have announced ambitious commitments—from AI data centers to energy infrastructure and defense purchases.
Both Saudi Arabia and Qatar emphasized large-scale purchases of U.S. goods—$142 billion in defense contracts from Saudi Arabia and $96 billion in aircraft orders from Qatar—which would support U.S. GDP through exports, but not count as domestic investment. 
Yet, the lack of specificity on most other announced projects suggests that much of the foreign capital may contribute indirectly by lowering financing costs rather than driving immediate, measurable increases in U.S. capital formation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45528339/us-assets-still-vital-in-global-portfolios-despite-debt-downgrade-blackrock">US Assets Still Vital In Global Portfolios Despite Debt Downgrade: BlackRock </a></li>
</ul>
Photo: Shutterstock

Politics

Econ #s

Trump's $6 Trillion Investment Deals Face Reality Check: Only A Fraction May Reach The Real Economy

Dividends

Press Releases

Lilly declares second-quarter 2025 dividend

Lilly announces transitions in executive leadership

Contracts

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

HSBC

Cantor Fitzgerald

Guggenheim

Morgan Stanley

Untitled design - 2025-03-31T165341.547

TNXP

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly

Eli Lilly (LLY) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL